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46 Poster Session Ion median donor graft mDC (0.81  106/kg recipient weight), or
pDC (0.67  106/kg), or monocyte (6.6  106/kg) counts. No cor-
relation was observed between acute and chronic GVHD as well as
relapse and APC counts. However, the mortality rate was signifi-
cantly higher in patients who received a greater dose of monocytes
(24/41 vs 11/41) (p5 0.003), with a trend for a more elevated TRM
(15/41 vs 8/41) (p 5 0.08), as compared to patients who received
a lower dose of monocytes. mDC and pDC counts did not correlate
with survival after transplant. In univariate analysis, TRM corre-
lated with advanced disease (p 5 0.03), age (p 5 0.039) and graft
monocyte and T cell counts (both p 5 0.03), whereas overall mor-
tality correlatedwith advanced disease (p\0.0001) and graft mono-
cyte counts (p 5 0.02). In multivariate analysis, monocyte counts
correlated with both TRM (p 5 0.06) and overall mortality (p 5
0.01).Conclusion:Donor CD141 cell dose in bone marrow grafts
independently correlates with mortality following allogeneic trans-
plantation suggesting a possible role of donormature accessory cells
in the regulation of post-transplant immunologic events.
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CLINICAL ISOLATION AND EX VIVO CULTURING OF CORD BLOOD-
DERIVED T CELLS FOR DONOR LYMPHOCYTE INFUSION
Uhlin, M.1,2, Ringden, O.2, Mattsson, J.2 1Karolinska Institute, Stock-
holm, Sweden; 2Karolinska Institute, Stockholm, Sweden.
Umbilical cord blood (CB) is a promising source of hematopoie-
sis for patients lacking a human leukocyte antigen (HLA)-matched
donor. CB can be collected easily and safely, is readily available, and
leads to successful long-term engraftment. Greater HLA disparity
can be tolerated between the recipient and donor CB compared
with bone marrow (BM) or peripheral blood (PB). CB T cells are
naive and express an immature phenotype, and CB grafts have lower
total nucleated cell (TNC) doses compared with BM. These factors
contribute to delayed time to engraftment and poor immune recon-
stitution in CB recipients.
CB transplantation has also been reported to be associated with
a lower risk of graft-vs-host disease (GVHD), which then reduces
the graft-vs-leukemia (GVL) effect. T cells are believed to be respon-
sible for the GVL effect. These cells now are used clinically as donor
lymphocytes to controlminimal residual disease or reinduction of re-
mission in relapsed leukemia after Allogenic bonemarrow or periph-
eral blood (PB) stem cell transplantation. It has been shown that
Allogenic ex vivo expanded suicide gene-modified PB T cells also
have the potential to cause GVHD and GVL effects. This raised
the question of whether ex vivo expanded CB lymphocytes (CBL)
also can be used as a tool for adoptive cellular immunotherapy.
PreliminaryResults:Wehave just recentlymanaged to establish
a protocol for massive expansion of CB derived T cells. We have
been able to show that cells can be expanded very efficiently more
then 100 fold, making them usable in the clinic suitable in number
for DLI after CB transplantation. We have further shown that the
expansion protocol doesnt skew the T cell population regarding
the phenotype, CD4:CD8 ratio as well as TCR usage profile. By ac-
tivating the expanded cells we have further confirmed the expanded
T cells capacity to efficiently produce pro-inflammatory cytokines.
Clinical Significance: Cord blood is increasingly used as stem cell
source in allogeneic SCT. However, in patients with malignant dis-
ease we hesitate to use CB since there is no possibility to increase the
GVL effect after CB SCT. If we can develop methods for expansion
of donor T cells from the CB unit given to the patient this may have
a dramatic impact on the treatment of rejection and relapse of the
underlying disease after CB transplantation. Today we lack treat-
ment options if the patient is showing signs leukemia relapse or re-
jection after CB transplantation.HEMATOPOIESIS/MESENCHYMAL CELLS120
GLYCOSAMINOGLYCANS AS ANTICOAGULANTS IN MUCOPOLYSAC-
CHARIDOSIS TYPE I (MPS I)
Tolar, J.1, Orchard, P.J.1, Key, N.2, Blazar, B.R.1 1University of
Minnesota, Minneapolis, MN; 2University of North Carolina School of
Medicine, Chapel Hill, NC.MPS IH (Hurler syndrome) is caused by severe mutations in
a-L-iduronidase (IDUA) gene, leading to accumulation of glycos-
aminoglycans (GAG). The disorder is lethal unless treated with he-
matopoietic stem cell transplantation (HSCT). When compared to
other recipients of HSCT,MPS IH patients have an increased inci-
dence of bleeding complications. To investigate whether this bleed-
ing propensity is related to theGAG accumulation we evaluated five
MPS IH patients (mean age: 1.1 years) prior to any therapy.We ob-
served that three of the five patients had an elevated activated partial
thromboplastin time (aPTT). We reasoned that the accumulation
of heparin sulfate, a hallmark of MPS IH, may serve as a heparin-
like anticoagulant. Consistent with this assumption, we have ob-
served a clear dose – effect relationship betweenGAG load and level
of anticoagulation. In this context, it is important to note that the
patient with the second highest value of urinaryGAG and aPTT ex-
perienced pulmonary bleeding on day 12 after HSCT requiring in-
tubation and ventilatory support for 25 days. We hypothesized that
endogenous GAG heparin sulfate exerts its antithrombotic effect
through inhibition of factor Xa. To test this hypothesis, we have as-
sessed anti-Xa levels in mice with IDUA deficiency, an animal
model of MPS IH. As expected, the anti-Xa level were not signifi-
cantly different in wild type C57Bl/6 mice and heterozygous
mice: 0.116 0.005 IU/cc plasma versus 0.106 0.004 IU/cc plasma
(p 5 0.2). Anti-Xa values of MPS IH mutant mice, however, were
significantly elevated when compared to the age-matched sex-
matchedwild type controls (0.196 0.05 IU/cc plasma versus 0.116
0.005 IU/cc plasma; p\0.001). In addition, we have observed that
GAG anticoagulant activity was neutralized by addition of the hep-
arinase. In conclusion, the current study links GAG produced in ex-
cess as a result of IDUA deficiency and a hemostatic defect in MPS
IHmice and humans. The implications of the current study are that
an impaired hemostasis may exist in untreated patients with MPS
IH, and that MPS IH patients with high urinary GAG are likely
to experience bleeding complications. This informationmay be use-
ful in identifying MPS IH patients at higher risk for bleeding, espe-
cially in the peri-transplant period, when GAG levels have not yet
normalized and additional, HSCT-related factors (e.g., thrombocy-
topenia and hepatic dysfunction affecting clotting factors) contrib-
ute to the high risk of bleeding.121
INTERACTION OF CD41CD251FOXP31 REGULATORY T CELLS WITH
HEMATOPOIETIC PROGENITOR CELLS REVEALS TWO DISTINCT PATH-
WAYS OF REGULATION
Urbieta, M.1, Barao, I.2, Chirinos, J.1, Panoskaltsis-Mortari, A.3,
Blazar, B.R.3, Murphy, W.J.2, Levy, R.B.1 1University of Miami School
of Medicine, Miami, FL; 2University of Nevada, Reno, NV; 3University
of Minnesota, Minneapolis, MN.
Naturally occurring CD41CD251Foxp31 regulatory T (Treg)
cells are responsible for a physiologically essential peripheral mech-
anism to maintain self tolerance. Several Treg cytokines which me-
diate immune regulation concomitantly possess hematopoietic
modulating activity, for example: transforming growth factor b1
(TGF- b1) and interleukin 9 (IL-9) have been found to have multi-
ple effects during early and late stages of myelopoiesis. Based on the
inhibition of CFU-IL3 observed after co-culture of BMCwith anti-
CD3/CD281IL-2 activatedTregs, we hypothesize that this regula-
tion occurs in a contact dependent manner through a mechanism
involving TGF-b1. Inhibition was not observed in transwell cul-
tures and we found that Tregs fail to inhibit CFU-IL3 activity
from MHC class II deficient BMC in vitro. Interestingly, CFU-
IL3 numbers were enhanced following transplant of syngeneic
B6-wt but not B6-Class II-/- BM in lethally conditioned recipients
depleted of Tregs, further supporting the notion that cognate inter-
action is required for this negative regulation to take place. IL-9 is
a T cell factor which can promote both growth and survival signals
capable of augmenting erythroid progenitor cell (PC) activity. Acti-
vated Treg cells co-cultured with syngeneic BMC populations as
well as Lin- fractions routinely resulted in a 3–4  augmentation
of CFU-E vs. control cultures lacking Tegs. Anti-IL-9 specific
mab but not isotype control Ig abolished the enhancement of
CFU-E activity. Moreover, Tregs from IL-9 KO mice inhibited
Poster Session I 47CFU-IL3 activity, but lost the capacity to enhance CFU-E. Addi-
tionally, a requirement for IL-9R signaling (IL-9Ra/gc) in BMC
was supported by the absence of Treg CFU-E enhancement of gc
KO marrow. Finally, Treg augmentation of CFU-E in transwell
cultures using B6-wt and B6-Class II-/- Lin- populations showed
that this enhancing activity: a) was not contact dependent and b)
did not require MHC class II expression on the targeted popula-
tions. These findings reveal two distinct pathways of regulation,
i.e. inhibition and enhancement as defined by cytokines, contact de-
pendency and an MHC class II requirement. Current studies have
found neither perforin or fasL are required to mediate either of
these pathways. In total, these results demonstrate for the first
time that Tregs can modulate activity which is critically important
to successful engraftment in clinical BMT, in addition to adaptive
and innate immune responses.122
G-CSF AND FLT3 LIGAND PROMOTE RECOVERY OF HEMATOPOIESIS AF-
TER TOTAL BODY IRRADIATION (TBI) WITHOUT HEMATOPOIETIC STEM
CELL SUPPORT
Georges, G.E.1,2, Pillai, J.N.1, Lesnikov, V.1, Lesnikova, M.1,
Yang, Y.-J.1, Aragon, A.1, Mielcarek, M.1,2 1Fred Hutchinson Cancer
Research Center, Seattle, WA; 2University of Washington, Seattle, WA.
Hematopoietic cells are highly sensitive to radiation damage and
their loss after radiation exposure results in lethal infections. We
asked if intensive supportive care and hematopoietic-specific cyto-
kine treatment after doses of TBI that were previously identified
as lethal would permit survival and promote recovery of endoge-
nous hematopoiesis without requiring hematopoietic stem cell sup-
port in the well-established dog model. Historical results showed
that after 4 Gy TBI and standard supportive care, only 1 of 28
dogs survived with recovery of endogenous hematopoiesis. The
new intensive supportive care regimen for dogs after irradiation in-
cluded an antibiotic use algorithm for empiric treatment of pro-
longed neutropenia and fever and blood transfusion and
intravenous fluid support. Intensive supportive care given to 60
dogs after TBI resulted in significantly improved survival compared
to the historical supportive care.With intensive supportive care, we
observed high rates of survival in dogs following exposure of up to 7
Gy TBI with complete endogenous hematopoietic recovery. Cyto-
kine treatment consisting of granulocyte colony stimulating factor
(G-CSF) alone or combined G-CSF and fms-like tyrosine kinase
3 (flt-3) ligand, (FL) given after TBI did not significantly improve
long term survival compared to recipients of intensive supportive
care alone, but it significantly decreased the duration of intensive,
expensive supportive care. For all cohorts receiving cytokines after













4 no 26 43 4/4
5 no 27 52 3/6
5 G-CSF 20 44 6/6
6 no 33 84 5/6
6 G-CSF 27 64 5/6
6 G-CSF 1 FL 18 53 5/5
7 no 55 77 5/6
7 G-CSF 24 64 5/5
7 G-CSF 1 FL 18 57 6/6
8 no* n/a n/a 0/4
8 G-CSF 1 FL 37 99 1/6
Survival at . day 1120.ive care alone (p\ 0.002). Treatment with the combination of G-
CSF (10 mg/kg/day) and FL (100 mg/kg/day), starting 2 hours after
TBI and continuing until recovery of ANC . 1000/mL resulted in
significantly more rapid recovery of ANC and platelets compared to
G-CSF alone. Follow-up of all surviving dogs .6 months after ir-
radiation showed sustained hematopoiesis and immune reconstitu-
tion. These studies show that in this model, hematopoietic stem
cells survive doses of TBI up to 7 and 8 Gy without requiring infu-
sion of either autologous or allogeneic hematopoietic stem cells,
that intensive supportive care is sufficient to permit reliable survival
after 7 Gy TBI, and that the cytokine combination of G-CSF and
FL is more effective than G-CSF in promoting rapid recovery of
neutrophils and platelets after moderately high dose TBI. The re-
sults are relevant for the treatment of victims of terrorist or acciden-
tal radiation exposure.123
INCREASED EXPANSION, HOMING AND ENGRAFTMENT OF CYTOKINE-
CULTURED CORD BLOOD-DERIVED CD341 CELLS BY TREATMENT
WITH NICOTINAMIDE, A FORM OF VITAMIN B3
Peled, T.1, Adi, S.1, Rosenheimer, N.G.1, Shoham, H.1, Daniely, Y.1,
Nagler, A.2, Rechavi, G.3, Amariglio, N.3, Hirsch, J.J.3, Fibach, E.4,
Peled, A.5 1Gamida Cell Ltd., Jerusalem, Israel; 2Chaim Sheba Medical
Center, Tel-Hashomer, Israel; 3Chaim Sheba Medical Center Tel
Hashomer 52621& Sackler School of Medicine Tel Aviv University,
Tel Aviv, Israel; 4Hadassah - Hebrew University Medical Center, Jeru-
salem, Israel; 5Hadassah - Hebrew University Medical Center, Jerusa-
lem, Israel.
Strategies to expandCD341 cells in vitro and to enhance their re-
populating activity in vivo may improve the clinical outcome of
transplantation. Alas, low engraftment efficacy after ex vivo expan-
sion limits the clinical utility of cultured CD341 cells.
Our study demonstrates that nicotinamide (NAM), a form of vi-
tamin B3 and an inhibitor of ADP ribosylation, attenuates the en-
graftment deficiency of cultured CD341 cells.
Treatment with NAM of cytokine-cultured cord blood (CB) de-
rived CD341 cells significantly increased the proportion of early
(CD38- CD341Lin-) HPC subsets within the expanded CD341
cell population.NAM-treated cultures had 7.5-foldmore SCIDRe-
populating Cells (SRC) than cytokine-alone treated cultures and 9
fold more SRC over the seeded number of SRC. Moreover, an en-
graftment advantage of NAM cultured cells was observed as early as
12 days after transplantation.
A mechanistic probe of NAM cultured cells demonstrated an ini-
tial slower proliferation rate of CD341 cells treated with NAM
than cells exposed to cytokines alone. Treatment with NAM en-
hances CD341 cells migration in response to CXCL12, the ligand
for CXCR4. Furthermore, NAM treatment stimulates significantly
the homing efficacy of cultured CD341 cells to the bone marrow of
NOD/SCID mice. This may explain, at least in part, the increased
engraftment efficacy of cells cultured with cytokines 1 NAM. Ge-
nome wide expression profiles of CD341 cells re-isolated from cy-
tokines and cytokines1NAM cultures demonstrate transcriptional
modulation byNAMof genes implicated in cell migration, motility,
adhesion, protein localization and cell cycle.
Our study unveils a novel activity ofNAMand suggests its clinical
utility in cord blood transplantation.124
MESENCHYMAL STEM CELLS SUPPORT EX VIVO UMBILICAL CORD
BLOOD EXPANSION BY A CONTACT-DEPENDENT ANTI-APOPTOTIC EF-
FECT
Chu, P.1, Huang, J.1, Prasath, A.2, Hwang, W.1 1SingHealth and
Duke-NUS Graduate Medical School, Singapore, Singapore; 2Singapore
General Hospital, Singapore, Singapore.
Aims: Ex vivo expansion of stem and progenitor cells in umbilical
cord blood (UCB) is enhanced by co-culture with mesenchymal
stem cells (MSC). We investigated the mechanism of this
